Currently out of the existing stock ratings of David Hoang, 13 are a BUY (56.52%), 8 are a HOLD (34.78%), 2 are a SELL (8.7%).

David Hoang

Work Performance Price Targets & Ratings Chart

Analyst David Hoang, currently employed at CITI, carries an average stock price target met ratio of 32.78% that have a potential upside of 15.2% achieved within 82 days.

David Hoang’s has documented 46 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 08-Aug-2024.

Wall Street Analyst David Hoang

Analyst best performing recommendations are on LBPH (LONGBOARD PHARMACEUTICALS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 12/13/2023. The price target of $113 was fulfilled within 27 days with a profit of $20.89 (22.68%) receiving and performance score of 8.4.

Average potential price target upside

ORTX Orchard Therapeutics PLC ALLK Allakos GOSS Gossamer Bio MLNT Melinta Therapeutics PRVB Provention Bio SRPT Sarepta Therapeutics NBIX Neurocrine Biosciences ACAD ACADIA Pharmaceuticals LBPH Longboard Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$16

$-0.7 (-4.19%)

$22

1 years 1 months 15 days ago
(05-Oct-2023)

1/2 (50%)

$0.05 (0.31%)

1

Buy

$15

$-1.7 (-10.18%)

$15

1 years 4 months 24 days ago
(27-Jun-2023)

2/2 (100%)

$9.77 (186.81%)

146

Buy

1 years 5 months 7 days ago
(13-Jun-2023)

1/2 (50%)

$88 (107.32%)

428

Buy

$5

$-11.7 (-70.06%)

1 years 8 months 7 days ago
(13-Mar-2023)

1/1 (100%)

$0.05 (1.01%)

1

Buy

$13

2 years 6 months 7 days ago
(13-May-2022)

1/2 (50%)

$-34.2 (-72.46%)

481

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is David Hoang is most bullish on?

Potential upside of $55.46 has been obtained for SRPT (SAREPTA THERAPEUTICS)

Which stock is David Hoang is most reserved on?

Potential downside of -$9.69 has been obtained for LBPH (LONGBOARD PHARMACEUTICALS)

What Year was the first public recommendation made by David Hoang?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?